NR4A1 and breast cancer: Molecular and histological evidence indicates that BC can be divided into 3 subtypes: BC expressing human epidermal receptor 2 (HER2+), hormone receptor-positive (ER+) or progesterone receptor positive (PR+) BC, and triple-negative BC (ER-, PR-, HER2-) [4, 5].